Testing 3 immunotherapy drugs for hard-to-remove soft tissue cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 1/2 study tests lurbinectedin plus two immune checkpoint medicines (ipilimumab and nivolumab) for soft tissue sarcoma that is hard to remove or has spread. It aims to see how well the combination works and how safe it is, especially for people with limited treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and can sign informed consent
- You have a confirmed diagnosis of locally advanced unresectable or metastatic soft tissue sarcoma
- Your cancer has measurable tumors and you are able to do normal daily activities fairly well (ECOG 0–1)
- You must have had the right kind of prior treatment: Phase 1 requires prior treatment; Phase 2 requires no prior treatment
- Your blood counts, liver, and kidney tests must be in acceptable ranges before starting
- You must be willing and able to follow all study visits and procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests trabectedin plus ipilimumab and nivolumab in people with advanced soft-tissue sarcoma that has already been treated. It aims to see how well this combination works and how safely it can be given.
This trial is testing whether a combination of two drugs—a targeted therapy (surufatinib) and an immunotherapy (envafolimab)—can help people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. Researchers will also use a person's genetic information and scans to see if they can predict who will benefit the most.
This trial studies a treatment called lifileucel that uses your own immune cells to fight the cancer. It is for people with a type of soft tissue sarcoma that has not responded to previous treatments.
This Phase 2 study tests a combination treatment for locally advanced or metastatic sarcoma that cannot be fully removed by surgery. It aims to shrink tumors and control disease by combining an injected cancer-killing medicine with two cancer-fighting drugs.
This trial tests a new combination of three drugs (zanzalintinib, ipilimumab, and nivolumab) for people with soft tissue sarcoma that has spread. The goal is to see if this combination can shrink or slow the cancer.
This Phase 2 study tests two medicines (cadonilimab and anlotinib) in people with advanced soft tissue sarcoma whose cancer grew after standard first treatment. It aims to see whether the combination can shrink tumors and improve safety.
Hear when a new Advanced Soft-tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.